Inactive Instrument

Insiders Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

End-of-day quote Nasdaq Other stock markets
- ^PTS	-

Apr. 03	Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	MT
Mar. 26	Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	Apr. 03	MT
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	Mar. 04	MT
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	Mar. 04	MT
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	Mar. 04	MT
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing	Dec. 15	MT
Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director	23-10-30	CI
Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director	23-07-03	CI
Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor	23-01-06	CI
Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer	22-11-02	CI
Protagonist Therapeutics Names Asif Ali Finance Chief	22-03-28	MT
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer	22-03-28	CI
Protagonist Therapeutics, Inc. Announces Resignation of Don Kalkofen as Principal Financial and Accounting Officer	22-03-23	CI
Protagonist Therapeutics, Inc. Announces Resignation of Don Kalkofen, Chief Financial Officer Effective on April 1, 2022	22-03-23	CI
Insider Sell: Protagonist Therapeutics	21-12-23	MT
Annexon : Names Larry Mattheakis as Chief Scientific Officer	21-10-04	MT
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology	21-09-07	CI
Protagonist Therapeutics, Inc. Announces Board Changes	20-08-13	CI
Protagonist Therapeutics, Inc. Announces the Appointment of Donald Kalkofen as Chief Financial Officer and Principal Accounting Officer, Effective May 28, 2019	19-05-29	CI
Protagonist Therapeutics, Inc. Announces Executive Changes	19-05-08	CI
Protagonist Therapeutics, Inc. Announces Management Changes	19-03-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

Insiders

Filters